Shield Therapeutics, a Switzerland-based specialty pharmaceutical company treating iron deficiency in the blood, has raised €8.2m ($12m) from Inventages Venture Capital, which acts as the corporate venturing unit for local chocolate maker Nestle, in its series A round.
The round gives a post-money valuation of €35m and will be paid in two equal tranches over the next two years to fund Shield’s next set of trials of its lead product.
In November, Shield sold a minority stake and…
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
